-29%

est. 2Y upside i

HealthcareSeries C

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Rank

#2909

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

NewLimit offers high-risk, high-reward equity with significant downside given preclinical stage and competition.

Last updated: July 19, 2026

Bull (10%)+85%

Positive Phase 1 data in 2027 leads to partnership and valuation increase to ~$6.2B, but diluted 15% for future raise, net 85% upside.

Base (50%)+5%

Steady clinical progress with no major catalysts; valuation grows modestly to ~$3.7B, diluted 15%, net 5% upside.

Bear (40%)-100%

Clinical setback or failure reduces equity value to zero; preference stack of $682M wipes out common stock.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Funding Intensity

22%

Total preferred stock of $682M represents 22% of current $3.1B valuation, creating moderate preference overhang.

Dilution Risk

moderate

With $435M raised in Series C, cash runway is ~3-4 years; but future clinical trials may require additional capital, potentially diluting common stock by 15-25%.

Secondary Liquidity

none

No secondary market activity reported; liquidity expected only at IPO or acquisition.

Other — 11 roles

View all 11 open roles at NewLimit →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on NewLimit's data — designed to show you've done your homework.

  • 1

    “What is the company's timeline to achieving clinical proof-of-concept and how does the board view financing options?”

  • 2

    “Given the competitive landscape with Altos Labs and Retro, what is NewLimit's differentiation and IP strategy?”

  • 3

    “How does the equity package compare to other private biotech opportunities, and what is the expected liquidity path?”

Community

Valuation Sentiment

Our model estimates -29% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.